[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Chengdu Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100606816","phase-4-prevention-of-stroke-recurrence-and-disease-progression-in-cerebral-small-vessel-disease-with-cilostazol-100606816",false,"NCT07180472","Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol","Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol: a Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosis of small artery occlusion ischemic stroke based on the TOAST classification, with symptom onset within the past 6 months.\n3. MRI findings indicating white matter hyperintensities, with Fazekas grade ≥2.\n4. mRS (modified Rankin Scale) score ≤2.\n5. CDR (Clinical Dementia Rating) score \\\u003C1.\n\nExclusion Criteria:\n\n1. Presence of other central nervous system (CNS) disorders, including CNS infections, immune-mediated or degenerative diseases, epilepsy, intracranial tumors, etc.\n2. History of drug or alcohol abuse, or severe psychiatric disorders.\n3. Diagnosis of malignant tumors.\n4. Severe hepatic dysfunction (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>3 times the upper limit of normal) or renal impairment (creatinine clearance \\\u003C25 mL\u002Fmin).\n5. Concomitant congestive heart failure.\n6. Systemic hemorrhagic disorders or bleeding tendency, including platelet count ≤100,000\u002Fmm³, coagulation abnormalities, gastrointestinal ulcers, or history of non-traumatic symptomatic intracranial hemorrhage.\n7. Conditions requiring long-term anticoagulation therapy, such as atrial fibrillation or deep vein thrombosis.\n8. Known allergy or contraindication to cilostazol, clopidogrel, or aspirin.\n9. Requirement for dual antiplatelet therapy during the study period (e.g., due to vascular stent implantation or symptomatic intracranial arterial stenosis).\n10. Inability to complete scale assessments or comply with long-term follow-up.\n11. Pregnancy, lactation, or planning to become pregnant.\n12. Participation in another interventional clinical trial.\n13. Any other condition deemed unsuitable for study participation by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},632,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is designed to evaluate whether cilostazol, an antiplatelet medication, is more effective and safer than aspirin or clopidogrel in preventing recurrent strokes and slowing disease progression in patients with cerebral small vessel disease (CSVD).\n\nCerebral small vessel disease is a common cause of lacunar stroke, cognitive decline, and long-term disability. Currently, aspirin and clopidogrel are widely used to prevent recurrent ischemic events, but their effectiveness in CSVD remains uncertain. Cilostazol has shown potential benefits in improving cerebral blood flow, protecting blood vessel walls, and reducing the risk of bleeding compared with traditional antiplatelet drugs.\n\nIn this randomized controlled trial, participants diagnosed with CSVD and recent lacunar stroke will be randomly assigned to receive cilostazol, aspirin, or clopidogrel. The main outcomes to be evaluated include the rate of recurrent ischemic stroke, progression of cognitive and functional impairment, MRI markers of CSVD (such as white matter hyperintensity, lacunes, microbleeds, and small infarcts), and safety outcomes including bleeding events.\n\nThe investigators hypothesize that cilostazol will reduce the risk of recurrent stroke and slow disease progression more effectively than aspirin or clopidogrel, with a comparable or lower risk of bleeding.\n\nBy comparing these three antiplatelet drugs in a rigorous, multicenter randomized controlled trial, this study will provide important clinical evidence to guide personalized treatment strategies for patients with CSVD. The results are expected to improve long-term outcomes, reduce disability, and enhance the quality of life for stroke survivors.",[27],"Cerebral Small Vessel Disease","NOT_YET_RECRUITING","2025-09-17",{"date":31,"type":32},"2025-09-23","ACTUAL",{"date":34,"type":21},"2025-09-20",{"date":36,"type":21},"2027-12-01",{"name":38,"class":39},"First Affiliated Hospital of Chengdu Medical College","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100537767","effectiveness-and-safety-of-bisaae-for-resistant-hypertension-100537767","NCT06282107","Effectiveness and Safety of BiSAAE for Resistant Hypertension.","Effectiveness and Safety of Bilateral Superselective Adrenal Arterial Embolization (BiSAAE) for Resistant Hypertension","Inclusion Criteria:\n\n* Male or female, aged between 30-65 years old.\n* Patients with resist hypertension (office systolic blood pressure ≥140 mmHg, and\u002For office diastolic blood pressure ≥90 mmHg, and\u002For 24-h average systolic blood pressure ≥130 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg\u002Fd, amlodipine 5 mg\u002Fd) for at least 4 weeks.\n* Informed consent signed and agreed to participate in this trial.\n\nExclusion Criteria:\n\n* Secondary hypertension\n* Adrenergic insufficiency.\n* adrenocortical insufficiency\n* Renal failure eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2\n* Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.\n* Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.\n* Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.\n* Fertile woman without contraceptives.\n* Coagulation dysfunction.\n* Pregnant women or lactating women.\n* Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.\n* Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.\n* Allergy or any contraindications for the study drugs, contrast agents and alcohol.\n\nHistory of depression, schizophrenia or vascular dementia.\n\n-Refused to sign informed consent","30 Years","65 Years",{"count":50,"type":21},72,[52],"NA","Hypertension is a common problem, affecting \\>1.1 billion people worldwide. Unfortunately, fewer than one in five treated patients with hypertension have their blood pressure (BP) under control. The increasing number of people with uncontrolled BP despite the use of three or more antihypertensive agents at optimal or maximally tolerated doses, with one of those agents preferably being a diuretic has been described as the resistant hypertension (RH). Achieving BP control is essential because patients with hypertension who have uncontrolled BP have significantly higher rates of all-cause, cardiovascular, heart disease and cerebrovascular disease mortality compared to normotensive individuals, whereas mortality risk in patients with well-controlled BP does not differ from that in normotensive individuals. There are a number of potential factors that contribute to the suboptimal control of hypertension, including medication non-adherence and prescribing inertia. This highlights the limitations of purely pharmacological approaches for the effective management of hypertension. In fact, the activation of the renin-angiotensin-aldosterone system (RAAS) and sympatho-adrenomedullary system play a pathogenic role in triggering and sustaining RH. Superselective adrenal arterial embolization (SAAE) is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines. Over the last decade, unilateral SAAE has emerged as a potential treatment option for patients with primary aldosteronism. Whether this approach can be extrapolated to patients with RH is unclear. We thus set out to perform a randomized trial to compare the safety and efficacy of bilateral SAAE with antihypertensive medications in treating RH.",[55],"Resistant Hypertension","2024-02-27",{"date":58,"type":32},"2024-02-28",{"date":60,"type":21},"2025-01-01",{"date":62,"type":21},"2026-12-31",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":92},"100533658","comparison-of-catecholamine-concentrations-in-venous-blood-during-selective-adrenal-artery-embolization-100533658","NCT06228677","Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization","Comparison of Catecholamine Concentrations in Adrenal Venous Blood and Peripheral Venous Blood During Percutaneous Selective Adrenal Artery Embolization in Hypertensive Patients With Primary Aldosteronism: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years with no gender restrictions.\n2. Adherence to the \"Primary Aldosteronism\" Diagnosis and Treatment Guidelines, confirmed diagnosis of primary aldosteronism following rigorous drug washout, and identification as either aldosteronoma or idiopathic aldosteronism via adrenal vein blood sampling.\n3. Blood pressure metrics that satisfy any of the subsequent conditions: a) Clinic-recorded blood pressure ≥140\u002F90mmHg; b) 24-hour ambulatory blood pressure monitoring results displaying average blood pressure \\>130\u002F80 mmHg or daytime readings \\>135\u002F85 mmHg.\n4. Adrenal CT scan revealing adrenal hyperplasia, nodular formations, or no significant morphological deviations.\n5. Hypertension history surpassing a duration of 6 months.\n6. Prior to screening, patients or their lawful guardians must provide a signed informed consent, sanctioned by the ethics committee.\n\nExclusion Criteria:\n\n1. Patients diagnosed with primary hypertension or secondary hypertension attributed to other etiologies.\n2. Female participants who are presently pregnant, lactating, or with intentions to conceive within the forthcoming year.\n3. Presence of significant systemic diseases, with particular attention to hepatic and renal dysfunction.\n4. Pronounced allergic reaction to contrast agents.\n5. Any other serious systemic diseases with a life expectancy of less than 12 months.\n6. Participants concurrently enrolled or expressing interest to participate in other clinical trials, the outcomes of which could potentially influence the results of the current study.\n7. The researcher's discretion deems the subject inappropriate for inclusion in the study for any given reason.",{"count":72,"type":21},196,"OBSERVATIONAL","To explore the relationship between perioperative blood pressure and catecholamine concentrations in adrenal venous blood and peripheral venous blood in hypertensive patients with primary aldosteronism (PA) who underwent percutaneous selective adrenal artery embolization (SAAE). In order to elucidate the related phenomena and possible mechanisms of blood pressure fluctuations caused by SAAE treatment in hypertensive patients with PA.",[55,76,77,78],"Secondary Hypertension","Secondary Hypertension to Endocrine Disorders","Primary Aldosteronism",[78,80,81,82,83],"Selective Adrenal Artery Embolization","catecholamine concentration","Adrenal Venous Blood","Blood Pressure Variability","RECRUITING","2024-01-19",{"date":87,"type":32},"2024-01-29",{"date":89,"type":32},"2023-09-18",{"date":62,"type":21},{"name":38,"class":39},1,""]